These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 39193973

  • 1. Therapeutic Effect of Apheresis and Buffy Coat-Derived Platelet Concentrates.
    Zimmermann R.
    Clin Lab; 2024 Aug 01; 70(8):. PubMed ID: 39193973
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of Therapeutic Effect of Apheresis Platelets and Buffy Coat-Derived Platelet Concentrates.
    Wang Z, Chen X, Zhang Y, Lu H, Ren L.
    Clin Lab; 2024 Aug 01; 70(8):. PubMed ID: 39193950
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
    Singh S, Shams Hakimi C, Jeppsson A, Hesse C.
    Transfus Apher Sci; 2017 Dec 01; 56(6):870-874. PubMed ID: 29126740
    [Abstract] [Full Text] [Related]

  • 5. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E, Figueiredo AC, Seghatchian J.
    Transfus Apher Sci; 2003 Aug 01; 29(1):13-6. PubMed ID: 12877887
    [Abstract] [Full Text] [Related]

  • 6. A rest period does not affect in vitro storage properties in apheresis platelets collected from the buffy coat layer.
    Wagner SJ, Seetharaman S, Kurtz J.
    Transfusion; 2012 Nov 01; 52(11):2427-31. PubMed ID: 22452313
    [Abstract] [Full Text] [Related]

  • 7. Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently?
    Nguyen KA, Chavarin P, Arthaud CA, Cognasse F, Garraud O.
    Blood Transfus; 2013 Jan 01; 11(1):152-3. PubMed ID: 22871820
    [No Abstract] [Full Text] [Related]

  • 8. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
    Bux J, Müller K, Misterek J, Mueller-Eckhardt C.
    Beitr Infusionsther; 1990 Jan 01; 26():99-102. PubMed ID: 1703912
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
    Paglia G, Sigurjónsson ÓE, Rolfsson Ó, Hansen MB, Brynjólfsson S, Gudmundsson S, Palsson BO.
    Transfusion; 2015 Feb 01; 55(2):301-13. PubMed ID: 25156572
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of hematologic values and transforming growth factor-beta and insulin-like growth factor concentrations in platelet concentrates obtained by use of buffy coat and apheresis methods from equine blood.
    Sutter WW, Kaneps AJ, Bertone AL.
    Am J Vet Res; 2004 Jul 01; 65(7):924-30. PubMed ID: 15281650
    [Abstract] [Full Text] [Related]

  • 14. Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.
    Abedi MR, Doverud AC.
    J Vis Exp; 2012 Dec 07; (70):e4414. PubMed ID: 23242463
    [Abstract] [Full Text] [Related]

  • 15. Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures.
    Noulsri E, Udomwinijsilp P, Lerdwana S, Chongkolwatana V, Permpikul P.
    Transfus Apher Sci; 2017 Apr 07; 56(2):135-140. PubMed ID: 28029568
    [Abstract] [Full Text] [Related]

  • 16. [Risk Assessment of Single-Donor (Apheresis) Platelet Concentrates and Pooled Whole-Blood-Derived Platelet Concentrates].
    Hitzler W, Hutschenreuter G, Wartensleben H, German Association of Blood Transfusion Services.
    Clin Lab; 2015 Apr 07; 61(7):869-75. PubMed ID: 26299092
    [Abstract] [Full Text] [Related]

  • 17. A critical comparison of platelet preparation methods.
    Vassallo RR, Murphy S.
    Curr Opin Hematol; 2006 Sep 07; 13(5):323-30. PubMed ID: 16888436
    [Abstract] [Full Text] [Related]

  • 18. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
    Vamvakas EC.
    Clin Lab; 2010 Sep 07; 56(7-8):263-79. PubMed ID: 20857891
    [Abstract] [Full Text] [Related]

  • 19. Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products.
    van de Geer A, Gazendam RP, Tool AT, van Hamme JL, de Korte D, van den Berg TK, Zeerleder SS, Kuijpers TW.
    Vox Sang; 2017 Feb 07; 112(2):173-182. PubMed ID: 28120426
    [Abstract] [Full Text] [Related]

  • 20. Overcoming the bottleneck of platelet lysate supply in large-scale clinical expansion of adipose-derived stem cells: A comparison of fresh versus three types of platelet lysates from outdated buffy coat-derived platelet concentrates.
    Glovinski PV, Herly M, Mathiasen AB, Svalgaard JD, Borup R, Talman MM, Elberg JJ, Kølle ST, Drzewiecki KT, Fischer-Nielsen A.
    Cytotherapy; 2017 Feb 07; 19(2):222-234. PubMed ID: 27887865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.